EX 10.1 FORBEARANCE AGREEMENT DATED JANUARY 16, 2009.

FORBEARANCE AGREEMENT

THIS FORBEARANCE AGREEMENT (this “Agreement”) is made as of the 16th day of
January, 2009, by and among XENOMICS, INC., a Florida corporation having offices
located at One Deer Park Drive, Suite F, Monmouth Junction, New Jersey
08852   (the “Company”), and those holders of the “Debentures” (as that term is
defined below) who have executed this Agreement (the “Undersigned
Holders”).  All of the holders of the Debentures are  referred to herein
collectively as the “Holders.”

WHEREAS, on or about November 14, 2006, each Holder purchased from the Company a
6% Convertible Debenture Note (each a “Debenture,” and all of them,
collectively, the “Debentures”).  All capitalized terms used in this Agreement
without definition shall have the meanings ascribed to them in the Debenture;
and

WHEREAS, the Company is in breach of various covenants, representations and
warranties under the Debentures and the other documents that were executed or
exchanged in connection therewith (the “Transaction Documents”), including
without limitation: (i) its failure to pay interest when due under the
Debentures, (ii) its failure to pay any and all late fees due under the
Debentures, (iii) its failure to timely file the initial Registration Statement
as required under the terms and conditions of the Registration Rights Agreement,
(iv) its failure to qualify the Registrable Securities (as that term is defined
in the Registration Rights Agreement) for quotation in a Trading Market for a
period of five (5) days’ starting on June 20, 2007, (v) its failure to satisfy
all amounts due and owing under the Debentures on the Maturity Date, and (vi)
its acceptance of financing in the principal amount of $120,000 from Kira
Sheinerman Ph.D. in 2008 that did not qualify as “Permitted Indebtedness” under
the Debenture and which was intended to assist the Company in meeting its
operating expenses.  The Company’s breaches under the Transaction Documents are
referred to herein singularly and/or collectively as the “Breaches”; and

WHEREAS, as a result of the Breaches, events of default have occurred and are
continuing under the Transaction Documents.  In addition to any other rights
that the Holders may have, upon an occurrence of an “Event of Default,” as
defined under the Debenture, the Company is required to redeem the outstanding
Debentures for an amount equal to the sum of (i) 130% of the principal amount,
(ii) all accrued and unpaid interest, and (iii) Late Fees and the costs of
collection (i.e., together the “Mandatory Default Amount”).  Furthermore, the
failure to file the Registration Statement requires the Company to make a
monthly payment to each Holder in an amount equal to 1.5% of the aggregate
purchase price paid by said Holder for the Debenture; and

WHEREAS, the Company has requested that the Holders waive all of the Company’s
defaults that have heretofore occurred or that exist as of the date hereof under
any of the Transaction Documents (the “Existing Defaults”); and

--------------------------------------------------------------------------------

WHEREAS, the Undersigned Holders are willing to waive the Existing Defaults in
accordance with  the terms and conditions set forth in this Agreement;

NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company and each of the
Undersigned Holders hereby agree as follows:

1.        Ratification of Existing Agreements.  Except as otherwise modified
herein, upon the satisfaction of the conditions set forth in Section 4 hereof,
all of the Company’s obligations, indebtedness and liabilities to the
Undersigned Holders, as evidenced by or otherwise arising under the Transaction
Documents are ratified and confirmed in all respects by the Company, subject to
the terms of this Agreement.

2.        Waiver of Default Events.  Subject to the satisfaction of the
conditions set forth in Section 4 of this Agreement, each of the Undersigned
Holders hereby agrees to waive each of the Existing Defaults, including but not
limited to any defaults that would give rise to the right to any payment under
Section 4(d) of the Debenture, and will forbear from taking any action on any of
the Existing Defaults which may be continuing from the date hereof until the
earlier of (a) the occurrence of a new Event of Default that is not cured within
the applicable grace or cure period, if any or (b) the Maturity Date (as revised
in Section 3(a) hereof).  Notwithstanding the foregoing, and so as to avoid any
confusion or doubt, the Undersigned Holders are not waiving any new Event of
Default (as defined in a Transaction Document) that may arise from and after the
date hereof, including without limitation, any Event of Default that may arise
in the case of the commencement of any legal proceeding against the Company
(whether the same relates to circumstances that occurred prior to or after the
date hereof) under Sections 8.a)ii or 8.a)iii of the Debenture, as modified by
this Agreement.  

3.        Amendments to Transaction Documents. Notwithstanding any provision to
the contrary set forth herein, the terms and conditions of the Transaction
Documents are hereby amended as follows:

(a)       The definition of “Maturity Date” in the Debenture is hereby amended
to December 31, 2010.

(b)       From and after the date hereof, and continuing until the first to
occur of an occurrence of a new Event of Default arising from and after the date
hereof (that is not cured within an applicable grace or cure period, if any) or
the Maturity Date (as revised in Section 3(a) above), the Company shall pay
interest to each Holder, on a quarterly basis commencing on April 1, 2009 (and
continuing on each July 1, October 1 and January 1 thereafter) on the aggregate
unconverted and then outstanding principal amount of the Debenture at a rate
equal to 11% per annum, by the issuance of non-assessable shares of Common Stock
at a conversion rate equal to $.50 per share.  The Company and each of the
Holders hereby agree that all such shares of Common Stock issued under this
Section 3(b) shall be “Registrable Securities,” as that term is defined in the
Registration Right Agreement, subject to the terms and conditions of the
Registration Rights Agreement, as amended by the terms of Section 3(c) hereof.

2

--------------------------------------------------------------------------------

(c)       The definition of the “Filing Date” in the Registration Rights
Agreement is hereby amended by deleting the date “May 14, 2007” and replacing it
with the date “December 31, 2010.”

(d)       Section 8.a)i. of the Debenture is hereby amended to read in its
entirety as follows:

          “i.       any default in the payment of (A) the principal amount of
any Debenture, or (B) interest (including Late Fees) on, or liquidated damages
in respect of, any Debenture, as and when the same shall become due and payable
(whether on a Conversion Date or the Maturity Date or by acceleration or
otherwise) which default is not cured within 5 Trading Days after written notice
from the Holder.

(e)       Section 8.a)ii. of the Debenture is hereby amended to read in its
entirety as follows:

          “ii.      the Company shall materially fail to observe or perform any
other covenant or agreement contained in this Debenture or any other Debenture
which failure is (1) not cured, if possible to cure, within the earlier to occur
of A) 10 Trading Days after notice of such default sent by the Holder or by any
other Holder, and (B) 15 Trading Days after the Company shall become or should
have become aware of such failure, and (2) said Holder commences a lawsuit
against the Company as a result of said uncured breach;”

(f)       Section 8.a)iii. of the Debenture is hereby amended to read in its
entirety as follows:

          “iii.     a default or event of default (subject to any grace or cure
period provided for in the applicable agreement, document or instrument) shall
occur under (A) any of the Transaction Documents and as a result thereof, a
lawsuit is commenced against the Company, or (B) any other material agreement,
lease, document or instrument to which the Company or any Subsidiary is bound
and a judgment in an amount not less than $100,000 has been entered against the
Company as a result thereof;”

(g)       Section 8.a)v.(vi) of the Debenture is hereby deleted.

(h)       Section 8.a)v.(vii) of the Debenture is hereby deleted.

(i)       Section 8.a)vii. of the Debenture is hereby amended by adding the
phrase “from and after December 31, 2010” to the end thereof.

(j)       Section 8.a)xii. of the Debenture is hereby amended to read in its
entirety as follows:

          “xii.     any monetary judgment, writ or similar final process shall
be entered or filed against the Company, any Subsidiary or any of their
respective property or other assets for more than $100,000, and shall remain
unvacated, unbonded or unstayed for a period of 45 calendar days (or such longer
period of time as agreed to by the Majority Holders).”

3

--------------------------------------------------------------------------------

(k)       Section 8 of the Debenture is hereby further amended by adding the
following new clauses:  

          “(ix)     the failure by the Company’s shareholders to elect the
“Debenture Holder Director” or the “Additional Director,” as those terms are
described in Section 7 of that certain Forbearance Agreement, dated as of
January 16, 2009, by and among the Company and the Holders (the “Forbearance
Agreement”), or their respective successors, in accordance with the terms and
conditions of the Forbearance Agreement, or the removal of the Debenture Holder
Director or the Additional Director without the prior written consent of the
“Majority Holders,” as defined in the Forbearance Agreement, while any of the
Debentures remain unpaid or unsatisfied;

          (x)       the occurrence of any of the following without the prior
written consent of at least a majority of the Executive Committee or
Compensation Committee of the Company’s Board of Directors, as the case may be,
including in any case the affirmative consent of the Debenture Holder Director
appointed and qualified in accordance with the terms of the Forbearance
Agreement, who will serve on both of those committees:  (1) the issuance of any
shares of Common Stock to any director, except as permitted under the
Forbearance Agreement, (2) the issuance of any options to purchase shares of
capital stock to any employee, consultant, and officer and/or director of the
Company, (3) the offer of any compensation package to any officer of the Company
or proposed officer of the Company that would enable said officer to purchase in
excess of 500,000 shares of capital stock of the Company (whether by option
grant, warrant or otherwise), provided, however, that  shares purchased by any
officer in the open market or in connection with a capital raise by the Company
will be exempt from these limitations, or (iv) the appointment or hiring of a
chief executive officer of the Company;

          (xi)      the breach by the Company of any of its obligations set
forth in the Forbearance Agreement; provided, however, if such breach is not
related to the Company’s failure to pay the Holder amounts due under the
Transaction Documents as modified by this Forbearance Agreement, such breach
shall not be deemed an Event of Default unless the Company fails to cure said
breach within thirty (30) days after its receipt of written notice thereof; or”

(l)       The definition of the term “Mandatory Default Amount” contained in the
Debenture is hereby amended to read in its entirety as follows:  

“The outstanding principal amount owed under this Debenture, plus all accrued
and unpaid interest and all other amounts, costs, expenses and liquidated
damages due in respect of this Debenture (but excluding any sums that were
satisfied pursuant to the terms of the Forbearance Agreement).”  

4

--------------------------------------------------------------------------------

In the event of a conflict between the terms and conditions set forth in Section
3 of this Agreement and the terms and conditions set forth in any of the
Transaction Documents, the terms and conditions of the Transaction Documents
shall be deemed to be amended so as to be consistent with the amendments set
forth in this Section 3.  For the avoidance of doubt, it is understood and
agreed that each of the Existing Defaults is being irrevocably waived by the
Holders, subject to the terms of Section 4 hereof, but the Holders are not
waiving any new Event of Default (as defined in a Transaction Document) that may
arise from and after the date hereof, including without limitation, any Event of
Default that may arise in the case of the commencement of any legal proceeding
against the Company (whether the same relates to circumstances that occurred
prior to or after the date hereof) under Sections 8.a)ii or 8.a)iii of the
Debenture, as modified by this Agreement.  

4.        Conditions Precedent to Holders Obligations.  Notwithstanding anything
to the contrary set forth herein, the terms and conditions of this Agreement
shall not be effective, and the Holders shall have no obligation to waive the
Events of Default under this Agreement, unless and until all of the following
conditions precedent have been satisfied:

(a)       Each and every Holder shall have executed this Agreement on or before
January 30, 2009, pursuant to which they agree to be bound by the terms and
conditions set forth herein.  In connection therewith, each Holder hereby
acknowledges that their respective signature page will be held in escrow by
Herrick, Feinstein LLP (the “Escrow Agent”) pursuant to the escrow agreement
attached hereto until the signature pages from all of the Holders have been
obtained.  The date upon which all of such signature pages are obtained by the
Escrow Agent is hereinafter referred to as the “Effective Date.”  Upon receipt
of all signature pages, the Escrow Agent shall forward a fully-executed copy of
each Agreement to each Holder. Notwithstanding the forgoing, in the event that
all such signature pages have not been received by the Escrow Agent on or before
January 30, 2009, the Escrow Agent shall destroy or return each signature page
to the respective Holder that signed the same, and all of the terms and
conditions of this Forbearance Agreement shall be null and void and of no force
and/or effect whatsoever.

(b)       The Company has issued the “Payment Shares” (defined below) to each
Holder as described below, which shares of Common Stock are issued in full
payment of: (i) all accrued and unpaid interest on the Debentures (including all
interest that has accrued at the 18% default rate from June 27, 2007 through the
date hereof) and late fees at the Interest Conversion Rate set forth in the
Debenture, and (ii) for all amounts due and owing under Section 2(b) of the
Registration Rights Agreement for the period from May 1, 2007 through the date
hereof. The Company and each of the Holders hereby agree that all such shares of
Common Stock issued under this Section 4(b) shall be “Registrable Securities,”
as that term is defined in the Registration Right Agreement, subject to the
terms and conditions of the Registration Rights Agreement, as amended by Section
3(c) hereof.  It is agreed and understood that the Company shall issue 2.655191
shares of Common Stock in return for each dollar owed on account of the items
listed in subsections (i) and (ii) of this Section 4(b) (such shares, the
“Payment Shares”), and that the issuance of said Payment Shares to the Holders
shall be deemed to satisfy the Company’s obligations to make payment to the
Holders under the Transaction Documents on account of any amounts due to the
Holders as of the date hereof by virtue of the Existing Defaults (whereas the
due date for the payment of the principal amounts due to the Holders under the
Debentures is, pursuant to this Agreement, changed to December 31, 2010).  It is
further agreed and understood that any Common Stock issued pursuant to this
Section 4(b) or Section 6(c) hereof shall be deemed “Exempt Securities” as
defined under the Transaction Documents whose issuance shall not trigger any
penalty or anti-dilution provision contained in the Transaction Documents.  

5

--------------------------------------------------------------------------------

(c)        The Holders shall have received a true and correct list of “Options,”
as that term is defined below; and the authorizations, on January 9, 2009, to
issue additional Options to Mr. John Brancaccio, and on October 2, 2008, to
issue Additional Options to Dr. Sheinerman and to Dr. Picker, shall have been
rescinded.

5.        Representations and Warranties.  

              A.    The Company hereby represents and warrants to the
Undersigned Holders that:

(a)       The execution, delivery and performance by the Company of this
Agreement have been duly authorized by all necessary action on the part of the
Company and do not contravene (i) the organizational documents of the Company,
(ii) any applicable law or regulation, or (iii) any other material agreement or
undertaking by which the Company is bound.

(b)       This Agreement is the legal, valid and binding obligation of the
Company and is enforceable against the Company in accordance with its terms.

(c)       There is no pending or, to the best of the Company’s knowledge,
threatened action or proceeding before any court, judicial body, administrative
agency or arbitrator which could materially adversely affect the ability of the
Company to perform its obligations under this Agreement.

(d)       The authorized capital stock of the Company consists of 100,000,000
shares of common stock, par value $.0001 per share and 20,000,000 shares of
preferred stock, authorized stated value $10.00 per share. There are 25,112.396
shares of common stock issued and outstanding and there are 95,600 shares of
preferred stock issued and outstanding.  The Company has only issued the
options, warrants, purchase rights, subscription rights, exchange rights or
other contracts or commitments that could require the Company to issue, sell, or
otherwise cause to become outstanding any of its capital stock (together,
“Options”) for 17,368,187 shares of capital stock of the Company, excluding
shares issuable upon conversion of the debentures.  A complete list of all
Options held by the officers, directors and employees of the Company, which
contains (i) the holder of each such Option, (ii) the date of issuance of each
such Option, (iii) the number of shares of the Company subject to each such
Option, (iv) the exercise price of each such Option, and (v) the expiration date
of each such Option, has been provided to the Holders contemporaneously
herewith.  Except as disclosed therein, there are no outstanding or authorized
Options, nor are there  any agreements or plans to issue any such Options other
than in accordance with the terms and conditions of this Agreement.  

6

--------------------------------------------------------------------------------

              B.    Each Undersigned Holder, hereby represents and warrants to
the Company, on behalf of itself, himself or herself, that:

(a) Power. Each Undersigned Holder has full right, power, authority and capacity
to enter into this Agreement and to consummate the transactions contemplated
hereby. Each Undersigned Holder represents that he, her or it owns the
Debentures and has not transferred any right, title or interest (including the
right to vote) in and to the Debentures.

(b) Authorization; Enforcement.  (a) The Undersigned Holder has the requisite
power and authority to enter into and perform his, her or its obligations under
this Agreement, (b) the execution and delivery of this Agreement by the
Undersigned Holder and the consummation by it of the transactions contemplated
hereby have been duly authorized by all necessary corporate action on the part
of the Undersigned Holder, if applicable and (c) this Agreement has been duly
executed and delivered by the Undersigned Holder.  To the knowledge of the
Undersigned Holder, no other proceedings on the part of the Undersigned Holder
are necessary to approve and authorize the execution and delivery of this
Agreement.  This Agreement, when executed and delivered, constitutes a valid and
binding obligation of the Undersigned Holder, enforceable against the
Undersigned Holder in accordance with its terms, except as such enforceability
may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to,
or affecting generally, the enforcement of creditors’ rights and remedies.

(c) No Conflicts.  The execution, delivery and performance of this Agreement by
the Undersigned Holder, and the consummation by the Undersigned Holder of the
transactions contemplated hereby will not (a) result in a violation of the
organizational documents of the Undersigned Holder, or (b) result in a violation
of any statute, law, rule, regulation, writ, injunction, order, judgment or
decree applicable to the Undersigned Holder, or (c) breaches any contractual
restrictions of the Undersigned Holder or employment covenant.  The Undersigned
Holder is not required to obtain any consent, authorization or order of, or make
any filing or registration with, any court or governmental or regulatory or
self-regulatory agency in order for it to execute, deliver or perform any of its
obligations under or contemplated by this Agreement in accordance with the terms
hereof.

(d) Each Undersigned Holder reiterates as of the date hereof, his, her or its
respective representations and warranties as set forth in Paragraph 3.2 of the
Securities Purchase Agreement, which is one of the Transaction Documents. Each
Undersigned Holder further acknowledges as of the date hereof, that any of the
shares of stock in the Company issued hereunder to an Undersigned Holder shall
be governed by the provisions of Paragraph 4.1, et. seq., of the Securities
Purchase Agreement imposing transfer restrictions and that the shares issued
pursuant to this Agreement shall be legended in accordance with Paragraph 4.1
(b) of the Securities Purchase Agreement.

6.        Affirmative Covenants.  The Company covenants and agrees with the
Debenture Holders that, for so long as any of the Debentures remain outstanding:

7

--------------------------------------------------------------------------------

(a) The Debenture Holder Director and the Additional Director, and their
respective successors, will be appointed to the Board of Directors in accordance
with the terms and conditions of Section 7 below.  

(b)  Unless otherwise agreed to in writing in advance by the “Majority Holders,”
as defined in Section 7(a) below, the compensation to be paid to each member of
the Board of Directors for service from and after the Effective Date of this
Agreement shall be limited to the “Annual Stipend Amount,” as defined below, and
all such compensation shall be paid as soon as reasonably practicable after the
expiration of the “Calculation Period.”  For purposes of this Agreement, the
“Annual Stipend Amount” shall mean a number of shares of Common Stock determined
by dividing (i) $25,000 by (ii) the average bid/ask price during the thirty (30)
day period (the “Calculation Period”) from and after the issuance of the
Company’s annual financial statements for the preceding fiscal year.  

(c) Unless otherwise agreed to in writing in advance by the Majority Holders,
the total number of options for the purchase of shares of Common Stock available
for issuance to all employees, consultants and officers and/or directors of the
Company shall be limited to twelve million five hundred thousand (12,500,000).  

(d)  Except for shares purchased by an officer or director in the open market or
in connection with a capital raise by the Company, the prior written consent of
a majority of the Board’s Compensation Committee, including that of the
Debenture Holder Director, shall be required for (i) the grant any options or
warrants to any director, officer, employee or consultant of the Company and
(ii) any compensation package offered to any officer or proposed officer of the
Company that would enable the officer to purchase in excess of five hundred
thousand (500,000) shares of capital stock (whether by option grant, warrant or
otherwise).

(e)  Any Options granted in violation of the terms and conditions of this
Forbearance Agreement shall be void ab initio.  

(f)   If the Debenture Holder director is timely designated by the Majority
Holders in accordance with the terms hereof, the Executive Committee of the
Board will be reconfigured to include a committee comprised of the Debenture
Holder Director, Kira Sheinerman, and one other director selected by a majority
of the Board of Directors.  The Executive Committee, in addition to its other
roles and responsibilities, will be updated on a timely basis and will be
involved with the search for a new Chief Executive Officer and with any and all
material negotiations regarding the Company,

(g)   The Company will use its best efforts to announce and hold an annual
meeting of its shareholders during the fourth calendar quarter of 2009 ( the
“Shareholders Meeting”) at which the shareholders shall be requested to (i)
subject to the provisions of this Agreement, elect the individuals to serve on
the Board of Directors of the Company until the Company’s next annual meeting of
shareholders and (ii) consider and act upon a proposal to amend the Company’s
Articles of Incorporation and Bylaws so as to memorialize the obligations of the
Company in Section 6 and Section 7 of this Agreement. In connection with the
foregoing, the Company hereby covenants and agrees to use its best efforts to
cause its Articles of Incorporation and the Bylaws to be amended at the
Shareholders Meeting to accomplish the foregoing and to file any and all
documents to effectuate the amendment.

8

--------------------------------------------------------------------------------

7.        Debenture Holder Director and Additional Director.  

(a)  The Holders holding a majority of all principal amounts remaining due and
payable by the Company under the Debentures (hereinafter referred to as the
“Majority Holders”) are hereby granted the right, in accordance with the terms
hereof, to nominate two (2) people to serve as members of the Board of Directors
of the Company consistent with the terms hereof until such time as all of the
Debentures are no longer outstanding (whether or not as the result of conversion
or payout or otherwise).  The Company shall use its best efforts to secure the
appointment of such nominees to the Board of Directors (including, if necessary,
by enlarging the number of members constituting the entire Board and appointing
such persons to fill the vacancies created thereby) until the Shareholders
Meeting, at which time the Company shall use its best efforts to achieve the
election of those nominees to the Board of Directors, including without
limitation, including designating such persons as management nominees and
soliciting and securing any and all requisite proxies for the election of those
nominees. The Debenture Holder Director and the Additional Director may be
nominated by the Majority Holders by their providing the Company with a written
notice of said consent (the “Consent”) of said nominee(s), together with a copy
of the nominee’s curriculum vitae.  The Majority Holders will have until ten
(10) days after the Effective Date to nominate the Debenture Holder Director and
until sixty (60) days after the Effective Date to nominate the Additional
Director. The nomination of the Debenture Holder Director and/or the Additional
Director shall be effective upon receipt by the Company of the Consent.  The
Company shall have seven (7) days from receipt of the nominations in which to
advise the Majority Holders whether the nominee fails to satisfy the criteria
set forth in Section 7(b) or Section 7(c), as the case may be, below.  If the
Company fails to provide such notice within said seven (7) day period, the
nominee will be deemed to have satisfied said criteria.  In the event that it is
determined that the nominee fails to meet the criteria set forth in Section 7(b)
(with respect to the Debenture Holder Director) or Section 7(c) (with respect to
the Additional Director), the Majority Holders and the Company’s Board of
Directors shall cooperate, in good faith, to find an acceptable candidate to
serve in such capacity.  Each of the Debenture Holder Director and the
Additional Director so chosen and accepted shall serve until (i) his or her
successor is designated by the Majority Holders, or (ii) his or her earlier
resignation, death or (as determined by the Majority Holders) inability to
serve, or (iii) all of the Debentures are no longer outstanding, whether due to
payment or conversion or otherwise.  The Debenture Holder Director or the
Additional Director may resign from the Board upon ninety (90) days advance
written notice to the Company, in which case the vacancy shall be filled by
Majority Holders nominating a new individual to fill the vacancy at least thirty
days prior to the expected vacancy, provided that the new nominee(s) satisfy the
requirements for the position of Debenture Holder Director or Additional
Director set forth herein, as the case may be.  In such event, the Majority
Holders shall determine which of the two (2) directors so nominated shall serve
as the Debenture Holder Director.  If the Debenture Holder Director or
Additional Director dies or vacates office without giving at least ninety days
advance written notice to the Company, the Company shall give the Holders
written notice thereof, and the Majority Holders shall have thirty days from the
date such notice is deemed given hereunder in which to nominate a successor.

9

--------------------------------------------------------------------------------

(b) The Debenture Holder Director (and any successor) must have earned a M.D. or
a Ph.D. from an accredited or well-established university and have a background
in biotechnology, and have served on the Board of Directors of a public
company.  In addition to the other authority granted to the Debenture Holder
Director herein, the Debenture Holder Director shall be appointed to serve as
the Secretary of the Company and shall serve on the Executive Committee of the
Board of Directors.

(c)  The Additional Director (and any successor) will be selected consistent
with the foregoing, and will be expected to have a science background (e.g., a
Ph.D. or M.D. or similar degree from an accredited or well-established
university), and will have experience either in the commercial world of medical
diagnostic testing or expertise in strategic mergers and acquisitions.

 (d)  It is agreed that, in addition to the foregoing, in order to qualify to
serve as the Debenture Holder Director, the Additional Director, or any
successor of either, the individual proposed by the Majority Holders must:

1.        not be an officer, director, manager, owner, trustee, or serve in a
managerial capacity, whether as an executive, independent contractor, consultant
or advisor, of any business organization that manufactures, licenses or sells
any products or services that directly compete with the products or services
offered or developed by the Company;

2.        not have engaged in any willful misrepresentation, fraud, or illegal
conduct with respect to the business or affairs of any business organization
that he or she has been associated with in any capacity which materially and
adversely affects, or can reasonably be expected so to affect, the operations,
prospects or reputation of the Company;

3.           not have been subject to any conviction of or plea of nolo
contendere to a felony or other crime involving moral turpitude, and must not
been convicted in a criminal proceeding or be a named subject of a pending
criminal proceeding (excluding traffic violations and other minor offenses);

4.        not have been subject to a petition under the federal bankruptcy laws
or any state insolvency law;

5.        not have been found by a court of competent jurisdiction in a civil
action or by the Securities Exchange Commission to have violated any Federal or
State securities law, and the judgment in such civil action or finding by the
Commission has not been subsequently reversed, suspended, or vacated;

10

--------------------------------------------------------------------------------

6.        not have been found by a court of competent jurisdiction in a civil
action or by the Commodity Futures Trading Commission to have violated any
Federal commodities law, and the judgment in such civil action or finding by the
Commodity Futures Trading Commission has not been subsequently reversed,
suspended or vacated;

7.        not have been the subject of any order, judgment or decree of any
court or governmental agency permanently or temporarily enjoining him or her
from engaging in any type of business practice.

8.        not have been disciplined by any by any self-regulating organization;
and

9.        agree, before assuming office,  that while serving as Debenture Holder
Director or Additional Director, he or she will at all times act in conformance
with, and will not violate, the fiduciary duties owed by a director of the
Company to its shareholders and to the Company under applicable law.

The Company hereby acknowledges and agrees that the failure of any nominee of
the Majority Holders who is timely designated and who satisfies the conditions
and qualifications set forth herein to be appointed and elected to the Board of
Directors in accordance with the terms hereof shall constitute a material breach
of this Agreement and an Event of Default under the Debentures.   

(e)       Notwithstanding anything to the contrary contained herein, if a
Debenture Holder Director (or his successor) is not timely nominated by the
Majority Holders in accordance with the terms hereof, then the Company shall not
be deemed to be in default hereunder or under the Debentures for taking action
without the consent of the Debenture Holder Director.

(f)       Directors’ Indemnification; Insurance.

(i)  To the extent commercially available at a cost reasonably consistent with
past costs, the Company shall at all times maintain directors’ and officers’
liability insurance comparable in terms and coverage to that maintained on the
date hereof for existing directors of the Company, and the Debenture Holder
Director and Additional Director shall be covered under such insurance.

(ii) The Company shall at all times, to the fullest extent permitted by
applicable law, provide for indemnification of, advancement of expenses to, and
limitation of the personal liability of, the members of the Board of Directors
of the Company. The same may not be amended, repealed or otherwise modified in
any manner adverse to any member of the Board until at least six years following
the date, in each case, that the Debenture Holder Director or the Additional
Director is no longer a member of the Board of Directors of the Company.

(iii) The Debenture Holder Director and the Additional Director who actually
join the Board of Directors of the Company in accordance with the terms hereof,
and are each intended to be a third-party beneficiary of the obligations of the
Company pursuant to this Section 7(e) and the obligations of the Company
pursuant to this Section 7(e) shall be enforceable by the Debenture Holder
Director and the Additional Director.

11

--------------------------------------------------------------------------------

(f)  It is agreed and understood that monetary damages would not adequately
compensate the Holders for the breaches of the provisions of Sections 6 or 7 of
this Agreement by the Company, that this Agreement shall be specifically
enforceable, and that any breach or threatened breach of this Agreement by the
Company shall be the proper subject of a temporary or permanent injunction or
restraining order. Further, the Company waives any claim or defense that there
is an adequate remedy at law for such breach or threatened breach.

8.        No Waiver.  Except as otherwise provided for in this Agreement,
nothing herein shall affect in any way the Company’s obligations or any of the
rights or remedies of the Holders arising under the Transaction Documents, and
the Holders shall not be deemed to have waived any of such rights or remedies
with respect to any event of default that has not already occurred or an event
or condition which hereafter, with notice or the lapse of time from and after
execution of this Agreement, or both, would become an Event of Default under the
Transaction Documents.

9.        Release of Holders.  In consideration of the Holder’s acceptance of
the terms of this Agreement, and provided that each Holder executes and delivers
this Agreement to the Escrow Agent on or before January 30, 2009 or any
extension of such Effective Date as signed by all of the Holders who have
executed this Agreement, and if the conditions to effectiveness of each Holder’s
waiver and forbearance set forth in Section 4 hereof are fully satisfied, then:

(a)     The Company, for itself and its parents, subsidiaries, affiliates,
predecessors,  successors and assigns (collectively, “Company Affiliates”), will
be deemed to have jointly and severally, released and forever discharged the
Undersigned Holders and each of their heirs and representatives (collectively,
“Debenture Holder Affiliates”), from any and all actions, cause and causes of
action, suits, debts, controversies, damages, judgments, executions, claims and
demands whatsoever, asserted or unasserted, in law or in equity which the
Company or any Company Affiliate ever had or now has against any Debenture
Holders or any Debenture Holder Affiliate upon or by reason of any matter,
cause, or thing relating to the exercise of any of their respective rights under
the Transaction Documents or under this Agreement; and

(b)     Each of the Undersigned Holders, for itself and its parents,
subsidiaries, affiliates, predecessors, heirs, successors and assigns
(collectively, “Releasing Holder Affiliates”), will be deemed to have jointly
and severally, released and forever discharged the other Holders and each of
their agents, heirs, executors, administrators, and representatives
(collectively, “Debenture Holder Affiliates”), from any and all actions, cause
and causes of action, suits, debts, controversies, damages, judgments,
executions, claims and demands whatsoever, asserted or unasserted, known or
unknown, in law or in equity, which the Undersigned Holders, or any of them, or
any Releasing Holder Affiliate, ever had or now has against any other Debenture
Holders or any Debenture Holder Affiliate upon or by reason of any matter,
cause, act or thing relating to the exercise of any of their respective rights
under the Transaction Documents or under this Agreement or relating to any act
or omission by the Debenture Holder while acting as an officer, director, agent
or representative of the Company.  Each Holder that is not a signatory to this
Agreement, and each Debenture Holder Affiliate, is intended to be a third-party
beneficiary of the obligations of the Undersigned Holder pursuant to this
Section 9(b) and the obligations of the Undersigned Holder pursuant to this
Section 9(b) shall be enforceable by each such Holder and such Debenture Holder
Affiliates.

12

--------------------------------------------------------------------------------

10.       Limitation and Conditions on Reimbursement For Attorneys Fees.  The
Company has agreed, if this Agreement is executed by all of the Holders, to
reimburse the Holders for attorneys fees, costs and expenses reasonably
incurred in connection with the review of this Forbearance Agreement; provided,
however, that the amount of attorneys fees, costs and expenses payable by the
Company to any Holder shall be limited to (a) a cash amount equal to the product
of (i) $50,000  (the "Cash Reimbursement"), and (ii) a fraction, the numerator
of which is equal to the   principal amount due and owing such Holder under his,
her or its   Debenture(s), and the denominator of which is equal to $2,170,500,
(said fraction hereinafter referred to as the "Holders Pro Rata Portion"), and
(b) a number of  shares of Common Stock  (par value $.0001 per share) equal to
the product of (I) 200,000, and (ii) the Holder's Pro Rata Portion.  Any request
for such reimbursement must be delivered to the Company in writing, together
with  documentation supporting the request, so that it is actually received
on or before January 30. 2009.  If a Holder fails to deliver such a request to
the Company on or before January 30, 2009, then that Holder will be deemed to
have waived any right or claim to reimbursement  for any attorneys' fees, costs
or expenses  under this Agreement, Paragraph 4.10 of the Securities Purchase
Agreement or otherwise.  In connection with the foregoing, the Company will
ensure delivery  to the Holders of (i) the shares of Common Stock within ten
days after this Agreement is released from escrow, and (ii) one-half of the Cash
Reimbursement within three business days of the Effective Date, and the other
half of the Cash Reimbursement within fifteen business days of the Effective
Date.  The Parties agree that fifty-percent of the Cash Reimbursement shall be
paid to the law firm of Harris Beach ("Harris"), as counsel for the Majority
Holders.  Accordingly, for the avoidance of doubt, $12,500 will be payable to
Harris  within three business days after the Effective Date, and $12,500
payable will be payable to Harris within fifteen business days after the
Effective Date.  The failure of the Company to make such payments to
Harris would constitute a default by the Company of its obligations under this
Agreement.         

11.       Assignment.  The Company may not assign any of its obligations
hereunder or under any related agreement to any person without the prior written
consent of the Undersigned Holder.  

12.       Voluntary Agreement.  Each of the undersigned represents and warrants
that it is represented by legal counsel of its choice, is fully aware of the
terms contained in this Agreement and has, voluntarily and without coercion or
duress of any kind, entered into this Agreement.

13

--------------------------------------------------------------------------------

13.       Notices.  Any notice, payment, demand, instruction or communication
required or permitted to be given by any provision of this Agreement (each,
hereinafter, a “Communication”) must refer to this Agreement and will be deemed
to have been given when delivered personally to the party designated to receive
such notice or on the third business day after the same is sent by certified
mail, postage and charges prepaid, or on the first business day after same is
sent by a nationally recognized overnight courier service. In each instance, in
order to be delivered to the Company, a Communication directed to the Company
must be addressed to Xenomics, Inc., One Deer Park Drive, Suite F, Monmouth
Junction, New Jersey 08852, Attn: Controller, with a copy to Kira Sheinerman,
Ph.D., c/o Rodman & Renshaw LLC, 1251 Avenue of the Americas, 20th Floor, New
York, NY 10020.  Any Communication to a Holder hereunder must be directed to the
last known address the Company has for such Holder or to such other address as
such Holder may designate by written notice to the Company.

14.       Entire Agreement; Binding Affect.  This Agreement, together with the
Transaction Documents and the escrow agreement attached hereto, constitute the
entire and final agreement between the parties, and supersedes and replaces and
prior or contemporaneous agreement, whether oral or written, between the
parties. This Agreement will inure to the benefit and bind the respective heirs,
administrators, executors, representatives, successors and permitted assigns of
the parties hereto.

15.       Severability.  If any clause or provision of this Agreement is
determined to be illegal, invalid or unenforceable under any present or future
law by the final judgment of a court of competent jurisdiction, the remainder of
this Agreement will not be affected thereby.  It is the intention of the parties
that if any such provision is held to be invalid, illegal or unenforceable,
there will be added in lieu thereof a provision as similar in effect to such
provision as is possible and that such added provision will be legal, valid and
enforceable.

16.       Headings.  All headings contained in this Agreement are for reference
purposes only and are not intended to affect in any way the meaning or
interpretation of this Agreement.

17.       Governing Law; Venue.  This Agreement shall be construed and
interpreted in all respects in accordance with the laws of the State of New
York, without giving effect to the conflict of law provisions thereof.  Each of
the undersigned specifically and irrevocably consents to the exclusive
jurisdiction and venue of the Federal and state courts located within New York
County, New York with respect to all matters concerning this Agreement and the
Transaction Documents and, to the fullest extent permitted by law, waives any
claim that such venue constitutes and inconvenient forum for such action.

18.       Counterparts.  This Agreement may be executed in counterparts, each of
which will be deemed an original document, but all of which will constitute a
single document, and it shall not be necessary in making proof of this Agreement
to present or account for more than one such fully executed counterpart.  For
all purposes, a facsimile copy of any party’s signature on this Agreement shall
be deemed to be an original.

19.       Amendment.  Neither this Agreement nor any of the provisions hereof
can be changed, modified, amended, waived, discharged or terminated, except by
an instrument in writing signed by the party against whom enforcement of the
change, modification, amendment, waiver, discharge or termination is sought;
provided, however, that any change, amendment or modification that has an
adverse effect on any other Holder shall not be effective until said change,
amendment or modification has been signed by said Holder.

14

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed as of the day and year first above written.

  XENOMICS, INC.  

By:

 

Name:

 

Title:

 

STATE OF NEW YORK ) ) SS.: COUNTY OF NEW YORK )

On the _____ day of January, in the year 2009, before me, the undersigned,
personally appeared _______________________, personally known to me or proved to
me on the basis of satisfactory evidence to be the individual whose name is
subscribed to the within instrument and acknowledged to me that he executed the
same in his capacity, and that by his signature on the instrument, the
individual, or the person upon behalf of which the individual acted, executed
the instrument.

    Notary Public

[Debenture Holder Signature Pages to Follow]

15

--------------------------------------------------------------------------------

SIGNATURE PAGE TO FORBEARANCE AGREEMENT
DATED AS OF JANUARY 16, 2009 FOR DEBENTURE HOLDERS

   

STATE OF _____________ ) ) SS.: COUNTY OF ___________ )

On the _____ day of January, in the year 2009, before me, the undersigned,
personally appeared ______________, personally known to me or proved to me on
the basis of satisfactory evidence to be the individual whose name is subscribed
to the within instrument and acknowledged to me that he executed the same in his
capacity, and that by his signature on the instrument, the individual, or the
person upon behalf of which the individual acted, executed the instrument.

  Notary Public